Clinical trial
Primary Chemotherapy With Adriamycin/Cyclophosphamide(AC) vs Taxotere/Xeloda(TX)…
NCT00352378 · National Cancer Center, Korea, Other · Completed
Key facts
| NCT number | NCT00352378 |
|---|---|
| Title | Primary Chemotherapy With Adriamycin/Cyclophosphamide(AC) vs Taxotere/Xeloda(TX) for Stage II and III Breast Cancer |
| Official title | A Phase III Randomized Study of Primary Chemotherapy With Adriamycin/Cyclophosphamide(AC) vs Taxotere/Xeloda(TX) for Stage II and III Breast Cancer |
| Lead sponsor | National Cancer Center, Korea, Other |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Anthracycline, Cyclophosphamide, Docetaxel, Capecitabine |
| Enrollment | 209 |
| Start date | Jun 1, 2002 |
| Primary completion | Oct 1, 2005 |
| Completion | Jan 1, 2006 |
| First posted | Jul 14, 2006 |
| Last update posted | Jun 27, 2011 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: